Merck reported robust revenue growth driven by strong performances in KEYTRUDA, GARDASIL, and Animal Health, despite the significant contribution from LAGEVRIO. Management maintained an optimistic tone with upgraded guidance for 2022, highlighting confidence in continued growth and pipeline advancements. These positive indicators are likely to support a favorable short-term movement in the stock.

[1]